Studies of complement genetics have changed the landscape of thrombotic
microangiopathies (TMAs), particularly atypical haemolytic uraemic syndrome (aHUS) …

Thrombotic microangiopathy (TMA) is a condition characterized by thrombocytopenia and
microangiopathic hemolytic anemia (MAHA) with varying degrees of organ damage in the …

Tremendous advances in our understanding of the thrombotic microangiopathies (TMAs)
have revealed distinct disease mechanisms within this heterogeneous group of diseases. As …

Atypical hemolytic uremic syndrome (aHUS), a rare variant of thrombotic microangiopathy, is
characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal …

Thrombotic microangiopathy (TMA) is a pattern of endothelial damage that can be found in
association with diverse clinical conditions such as malignant hypertension. Although the …

Atypical HUS (aHUS) is a disorder most commonly caused by inherited defects of the
alternative pathway of complement, or the proteins that regulate this pathway, and life …

Atypical hemolytic uremic syndrome (aHUS) is a rare, genetic, progressive, life-threatening
form of thrombotic microangiopathy (TMA) predominantly caused by dysregulation of the …

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy caused by
uncontrolled activation of the alternative pathway of complement at the cell surface level that …

Uncontrolled complement activation is central to the occurrence of atypical hemolytic uremic
syndrome (aHUS) and can result in thrombotic microangiopathies (TMAs). These terms …

[EN] Haemolytic uraemic syndrome (HUS) is a clinical entitydefined as the triad of
nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which …